Shire's CEO Flemming Ornskov says he's focused on the specialist pharma's emerging ophthalmics division - and open to fresh innovative collaborations like that signed this week with Parion Sciences.
Future collaborations to build Shire PLC 's ophthalmology activities could in theory resemble that signed this week with US-based biotech Parion Sciences Inc., whereby the Dublin-based, London-listed group acquired worldwide rights to a Phase II dry eye disease drug dubbed P-321.
Or, they could be struck with academia partners – provided they are innovative and meet unmet medical needs,
The company hopes the drug will become the standard of care rescue treatment in asthma.
In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
